about
HIV type 1 Gag as a target for antiviral therapyThe development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicHIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionStructure of a Monomeric Mutant of the HIV-1 Capsid ProteinStructure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse TranscriptaseMonitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine seriesCharacterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assayStructural and functional insights into the HIV-1 maturation inhibitor binding pocketCalcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic InterventionStructure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396Peptide and protein-based inhibitors of HIV-1 co-receptorsNanotechnology and HIV: potential applications for treatment and prevention.Maturation of the HIV-1 core by a non-diffusional phase transition.Cyclic peptide inhibitors of HIV-1 capsid-human lysyl-tRNA synthetase interactionAlpha-tocopherol transfer protein disruption confers resistance to malarial infection in mice.Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.Assembly and replication of HIV-1 in T cells with low levels of phosphatidylinositol-(4,5)-bisphosphate.Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domainAntiviral activity of a zymolytic grain based extract on human immunodeficiency virus type 1 in vitro.Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?HIV-1 drug discovery: targeting folded RNA structures with branched peptides.Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cellsIdentification of cellular proteins required for replication of human immunodeficiency virus type 1New insights into HIV assembly and trafficking.Phase diagrams map the properties of antiviral agents directed against hepatitis B virus core assemblyThe (5Z)-5-Pentacosenoic and 5-Pentacosynoic Acids Inhibit the HIV-1 Reverse Transcriptase.Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.Twenty-five years of translational medicine in antiretroviral therapy: promises to keep.Coming of age: reconstruction of heterosexual HIV-1 transmission in human ex vivo organ culture systems.The Nef-infectivity enigma: mechanisms of enhanced lentiviral infection.Morphogenesis of the Infectious HIV-1 Virion.Characterization of HIV-1 integrase interaction with human Ku70 protein and initial implications for drug targeting.RNA Viruses and RNAi: Quasispecies Implications for Viral EscapeNanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120.Some mechanisms of FLIP expression in inhibition of HIV-1 replication in Jurkat cells, CD4+ T cells and PBMCs.The conformational feasibility for the formation of reaching dimer in ASV and HIV integrase: a molecular dynamics study.Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
P2860
Q24614498-8676AFBF-EB65-4612-A6E7-994211B46193Q24655011-A50E407C-1082-4814-8338-8C3DAEA22918Q27666355-510D9FDB-94FB-44D2-B137-BBC9A79876C8Q27675009-AD637E0B-DF41-4EAE-B757-3E2A8A5E1EAFQ27680709-23EC1BE3-6E6D-4ED0-A93C-2989A6DC721DQ27683977-A8F590E3-8A7E-4729-A306-17EED8F2275FQ28477791-4A98A74C-AF70-46A8-BB8A-C9105F21BE14Q28485054-AA47667C-C846-482C-BA2B-C2C24CAD5194Q28550701-4CAE2ECF-D929-401A-93F3-DC289379E15EQ28828191-5835E8AF-F67C-4C68-B103-BC6C2AAA6261Q30352117-3A2474EE-5A6A-478D-8467-28C6EB6965BDQ30393980-F53DDEB0-3DBE-4C6A-AF6F-29AF40C5F22BQ30613887-1DB02065-0D15-4106-86E4-948A39740624Q31046491-E8AF0A6C-D15A-4A79-9D71-C040F19A8E07Q33820304-A1A8EF0D-15AC-4CC8-BBDC-8B4BAEA5012CQ34163977-50AABE45-6C06-455C-AF80-2715CEA71635Q34179686-B3F2B453-D744-438F-AAF3-EB0C1ECCAC95Q34742397-541F4E9D-3238-42D2-8C3A-78EB5F5A03CDQ34989840-11B6E97E-CC94-4329-9CEC-157019D39470Q35207566-FEAF1ECD-7D2E-4135-9056-7E7A283B1AE6Q35544355-03B92598-F76E-42E5-A1A0-2F541D9552A3Q35626292-E8DF9240-64DD-4DD7-A144-A1DBE64D30E2Q35746131-BE1444D1-E8DB-43A8-8DB1-C7A4D07B407AQ36234765-AAFCC4CE-3176-49F8-B388-BE3D39B8091AQ36250367-C5330608-09DA-4955-8408-6153BE732B77Q36307738-42F45B05-686B-42F7-9419-E6FE161FA529Q36667005-192B6D9E-5FAC-4B81-9AEC-40D1898940BBQ36826857-31A550B4-4A18-4C8C-9C35-6C6AF179E205Q37036503-0B6F7E97-3034-45EC-AA06-8B1B105A8E66Q37770831-C594CEA5-D14F-4E70-B566-E55238964318Q37856708-F7469DA2-A4C0-49E3-9C26-4C1712D18FD0Q37959034-3DC737A3-3451-46F1-BC4A-969C8E78EB16Q37967727-975A267F-B994-43C8-AD9F-991DA66F9F4FQ38287721-6D9F7E48-359D-47D5-8B1B-5A7B0001D797Q38535397-F40C8925-30C7-4CC1-93E4-63B0408BB732Q38622404-220270F6-86DF-45DC-9278-43144BC3E88FQ39041742-B4065170-C279-4DA9-9DB8-354953F1B62DQ39148849-0E8C66C5-1F57-4FD1-AACC-69420E71D75FQ39195267-1B7E7CB0-E093-4660-857D-894A3B5DED93Q39200129-763D66A1-C688-4E96-BF53-F7F00D820BDA
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Novel approaches to inhibiting HIV-1 replication.
@ast
Novel approaches to inhibiting HIV-1 replication.
@en
type
label
Novel approaches to inhibiting HIV-1 replication.
@ast
Novel approaches to inhibiting HIV-1 replication.
@en
prefLabel
Novel approaches to inhibiting HIV-1 replication.
@ast
Novel approaches to inhibiting HIV-1 replication.
@en
P2860
P1433
P1476
Novel approaches to inhibiting HIV-1 replication
@en
P2093
Eric O Freed
P2860
P304
P356
10.1016/J.ANTIVIRAL.2009.09.009
P577
2009-09-24T00:00:00Z